Get the latest news, insights, and market updates on TNDM (Tandem Diabetes Care, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
1 Small-Cap Stock with Exciting Potential and 2 Facing Headwinds
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats. Feb 3, 2026 - $TNDM
Is Tandem Diabetes Care (TNDM) Starting To Look Attractive After Prolonged Share Price Weakness?
If you are wondering whether Tandem Diabetes Care at around US$19.89 is starting to look like value or still carries too much risk, you are not alone. The stock has seen a 0.1% decline over the last 7 days, a 7.7% decline over the last month and a 46.3% decline over the past year, with a 55.8% decline over 3 years and an 80.2% decline over 5 years. Recent news around Tandem Diabetes Care has focused on its position in insulin pump therapy and how its products fit into the broader diabetes... Feb 2, 2026 - $TNDM
3 Stocks Under $50 That Fall Short
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market. Jan 30, 2026 - $TNDM
Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates
Hologic (HOLX) delivered earnings and revenue surprises of -4.46% and -2.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Jan 29, 2026 - $TNDM
Improved Growth Outlook and Better-Than-Expected Results Boosted Tandem Diabetes Care (TNDM) in Q4
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a quarter shaped by optimism around potential monetary easing and caution related to economic growth and valuations. Early gains were driven by strong AI-related earnings and the […] Jan 27, 2026 - $TNDM
3 Reasons to Avoid TNDM and 1 Stock to Buy Instead
Over the past six months, Tandem Diabetes has been a great trade, beating the S&P 500 by 9.6%. Its stock price has climbed to $19.83, representing a healthy 17.8% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move. Jan 26, 2026 - $TNDM
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.